Fujishima Hiroshi, Fukagawa Kazumi, Tanaka Mari, Uchio Eiichi, Takamura Etsuko, Nakagawa Yayoi, Miyazaki Dai, Fukushima Atsuki, Okamoto Shigeki, Yokoi Norihiko
Department of Ophthalmology, International University of Health and Welfare, Mita Hospital, Tokyo, Japan.
Ophthalmologica. 2008;222(4):232-9. doi: 10.1159/000130072. Epub 2008 May 8.
To evaluate the efficacy of a combined therapy with levocabastine hydrochloride ophthalmic suspension and pemirolast potassium ophthalmic solution compared to single therapy with levocabastine hydrochloride ophthalmic suspension alone.
Thirty-two allergic conjunctivitis patients were randomized to combined-treatment (n = 15) or single-treatment groups (n = 17). The improvement of subjective symptoms as well as objective findings were evaluated.
The degree of improvement was significantly higher in the combined-treatment group for lacrimation (p = 0.008) among the subjective symptoms, for conjunctival edema (p = 0.030), eyelid edema (p = 0.032) and conjunctival papilla formation(p = 0.040) among the objective findings.
Both objective assessments and subjective symptoms of allergic conjunctivitis showed the greatest improvements when patients were treated with combined therapy as compared to single-agent therapy. The enhanced benefits of combined therapy may result from these agents having different mechanisms of action.
评估盐酸左卡巴斯汀眼用混悬液与吡嘧司特钾滴眼液联合治疗相较于单独使用盐酸左卡巴斯汀眼用混悬液单一治疗的疗效。
32例过敏性结膜炎患者被随机分为联合治疗组（n = 15）和单一治疗组（n = 17）。评估主观症状及客观体征的改善情况。
主观症状中，联合治疗组在流泪方面的改善程度显著更高（p = 0.008）；客观体征方面，联合治疗组在结膜水肿（p = 0.030）、眼睑水肿（p = 0.032）和结膜乳头形成（p = 0.040）方面的改善程度显著更高。
与单一药物治疗相比，过敏性结膜炎患者接受联合治疗时，客观评估和主观症状的改善最为显著。联合治疗增强的益处可能源于这些药物具有不同的作用机制。
Zotero 插件